Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06836232 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
A Phase 2 study of Recurrent Pericarditis, sponsored by Zomagen Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 16
- Study locations
NCT06836232 is a Phase 2 study of Recurrent Pericarditis that is actively recruiting participants, run by Zomagen Biosciences. The registered enrollment target is 50 participants, below the 214-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (77% lower). The trial reports 16 study locations across 13 states.
The verdict
NCT06836232, a Phase 2 study of Recurrent Pericarditis, is actively recruiting participants, sponsored by Zomagen Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include up to 30 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A * A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A * An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period Cohort B will include up to 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C * A 14-day Follow-Up Period
Conditions Studied
Interventions
- DRUG VTX2735
Study Locations (16)
Illinois
- Local Site #840008 - Chicago
- Local Site #840002 - Park Ridge
Texas
- Local Site #840019 - Houston
- Local Site #840001 - Houston
Virginia
- Local Site #840018 - Charlottesville
- Local Site #840004 - Richmond
Arizona
- Local Site #840012 - Tucson
California
- Local Site #840014 - Orange
Florida
- Local Site #840016 - Saint Augustine
Kentucky
- Local Site #840011 - Owensboro
Massachusetts
- Local Site #840010 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-01-28 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06836232
The ClinicalTrials.gov registry entry for NCT06836232 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 214-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (77% lower). The listed sponsor is Zomagen Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Pericarditis appearing as the primary indexed condition, and to 1 intervention - of which VTX2735 is the first listed.
NCT06836232 reports 16 study locations spanning 13 distinct geographic areas - top geographies include Illinois, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT06836232 about?
NCT06836232 is a clinical study titled "An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis". This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include up to 30 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week ...
What is the current status of trial NCT06836232?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-01-28. Estimated completion is 2026-10.
What conditions does trial NCT06836232 study?
This clinical trial studies the following conditions: Recurrent Pericarditis.
What interventions are being tested in trial NCT06836232?
The interventions under investigation include: VTX2735 (DRUG).
Who is sponsoring clinical trial NCT06836232?
This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06836232 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Pericarditis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transition to KPL-387 Monotherapy Dosing & Administration Study
RECRUITING · Phase 2
-
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
RECRUITING · Phase 2
-
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
RECRUITING · Phase 3
-
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.